Thermo Fisher Scientific (TMO-N)

Has longed liked this and it's long been a good performer, but it has struggled since peaking in end-2021 and pulled back in 2022, and sideways ever since. TMO benefitted in 2020-1 as drug companies spent a fortune dealing with Covid and needed TMO's medical machines. From Oct. 2023 to Sept. 2024, shares rose 51%, but is down 18% since then. But they last reported a mixed quarter: a slight miss in revenue though a slight beat in earnings and soft guidance. It sold off and hasn't stopped, though announcing a $4 billion share buyback last month helped. He expects a graudal improvement as business picks up int he next two years. Trades at only 22x PE 2025 vs. 30x historically, so it's cheap now.

The merger doesn't take effect until Jan. 1; she see few changes after the merger. Price has disappointed post-Covid, given inventory and interest rate hurdles. With rates falling, she expected health care to resume, but she thinks that spend is delayed. The stimulus in China will help. With the new US president, we also don't know what will happen to this sector. But she likes TMO's fundamentals, and would buy at these levels.

Touches all aspects of bio-pharma industry. For example, helps run pharmaceutical trials, and helps build and design new drugs. Everything you need, such as electron microscopes, to create new drugs and products. 

Weak coming out of Covid, as there was too much inventory in the system. Now primed to see revenue growth reaccelerate. Last time, Trump was favourable to healthcare and biotech. Low multiple relative to its historical average. Yield is 0.3%.

Scores 10/10 in her book. A global leader in scientific devices. Earnings grew double digits in the past 5 years and she expects steady growth to come. They raised EPS guidance from $21.35 to $22.00. There's 17% upside.

Still owns business. Excellent business. Expecting earnings to grow. Ability to grow in USA very good. Slow and steady growth - defensive name. Very good for a long term investor. 

All the tools and services that the healthcare industry needs, so you get diversity with just the one stock. Very well managed. Long-term growth targets are 7-9%. Always improves margins. China is about 8% of revenues, a bit weaker. Biotech funding dried up with higher rates. Inventory destocking. Hopefully, those 3 factors are behind them.

Likes it. Great job improving ROE, pretty stable sales growth. Estimate for 2025 is 11-12% earnings growth. Technically, sets up well.

Benefitted from Covid, but afterwards there was too much inventory. But the PE fell from 30x to 20x, and is exiting the excess and entering a long cycle. Will grow earning 10-15% including by acquisition. Healthcare/pharma/biotech he expects will grow.

It made a buy list today and deserved it. They're starting to see a rebound after Covid. They have a lot of diagnostic equipment that's widely used across healthcare. Shares are earnings are coming out of the doldrums and starting to move up.

World leader, dominates the industry. Not cheap, but solid long-term grower.

Still very positive, especially as spending by pharmaceuticals is getting more robust.

They delivered today a strong earnings and revenue beat as they raised their full-year forecast. Thinks this the last quarter of revenue shrinkage before it gets a major rise in the second half of 2024.

Subdued returns. A leader, critical player in its sector. Stock's lagged due to inventory destocking, higher interest rates, and softer Chinese economy. These issues are largely resolved.

It is the leading company for testing new drugs. It has grown from acquisitions and is now growing at a rate of 5 to7% a year. Buy and hold.

Higher interest rates saw weaker funding in biotech. China had weak demand, though only about 8% of revenues. Still likes it long term for a picks and shovels play.